Looking back at mosunetuzumab treatment for follicular lymphoma that returned or stopped responding
Reviews how adults with follicular lymphoma responded to mosunetuzumab after earlier treatments.
Plain-language title generated from the registry record
Registry title: Study to Evaluate the Response to Treatment With Mosunetuzumab in Relapsed/Refractory Follicular Lymphoma (FL) After at Least Two Lines of Therapy, Within the Compassionate Use Program (CUP).
Key facts
- Where
- Milan, ItalySee the site
Where in Italy
- IRCCS Ospedale San RaffaeleMilan, ItalyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Andrés José Maria Ferreri
- Trial code
- NCT07278921
- Record updated
- 3 February 2026
- Original description
Retrospective, multicenter observational study to evaluate the response to treatment with Mosunetuzumab in relapsed/refractory Follicular Lymphoma (FL) after at least three lines of therapy, within the Compassionate Use Program (CUP).Read full original descriptionShow less
Retrospective, Multicenter Observational Study to Evaluate the Response to Treatment With Mosunetuzumab in Relapsed/Refractory Follicular Lymphoma (FL) After at Least Two Lines of Therapy, Within the Compassionate Use Program (CUP).
Retrospective, multicenter observational study to evaluate the response to treatment with Mosunetuzumab in relapsed/refractory Follicular Lymphoma (FL) after at least three lines of therapy, within the Compassionate Use Program (CUP).
Inclusion: Adult patients (>18 years) with follicular non-Hodgkin's lymphoma, undergoing at least two lines of therapy, treated with mosunetuzumab under a compassionate use program; Patients who have signed informed consent for treatment.
Exclusion: Patients with other types of cancer/lymphoma; Age <18 years; Patients not eligible for the Mosunetuzumab compassionate use program.